Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF).
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2010
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 20 Feb 2010 New trial record